Cell-Based Immunotherapy of Gliomas
- PMID: 29990977
- DOI: 10.1159/000469683
Cell-Based Immunotherapy of Gliomas
Abstract
Current cell-based immunotherapeutic strategies attempt to produce and maintain an immune response against glioma cells by artificially stimulating the immune system using passive and/or active approaches. Cellular immunotherapy is taken to mean the administration of live immune cells that either have immune effector capabilities themselves (passive immunotherapy) or engender a downstream antitumor response (active immunotherapy). Passive cellular immunotherapy most often takes the form of the adoptive transfer of a range of cell types, whereby antitumor immune cells from a patient (or allogeneic donor) are created, activated, and/or expanded ex vivo and subsequently administered back to the patient to directly attack the neoplasm. Active cellular immunotherapy approaches for the treatment of malignant gliomas have most often taken the form of dendritic cell (DC)-based vaccines.
© 2018 S. Karger AG, Basel.
Similar articles
-
Cellular immunotherapy for malignant gliomas.Expert Opin Biol Ther. 2016 Oct;16(10):1265-75. doi: 10.1080/14712598.2016.1214266. Epub 2016 Jul 29. Expert Opin Biol Ther. 2016. PMID: 27434205 Free PMC article. Review.
-
Dendritic cell vaccines.Adv Exp Med Biol. 2012;746:187-200. doi: 10.1007/978-1-4614-3146-6_15. Adv Exp Med Biol. 2012. PMID: 22639169 Review.
-
The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.Curr Neurol Neurosci Rep. 2017 Jun;17(6):50. doi: 10.1007/s11910-017-0754-x. Curr Neurol Neurosci Rep. 2017. PMID: 28488122 Review.
-
Immunotherapy for glioma: promises and challenges.Neurosurg Clin N Am. 2012 Jul;23(3):357-70. doi: 10.1016/j.nec.2012.05.001. Neurosurg Clin N Am. 2012. PMID: 22748649 Review.
-
Galectin-1 and immunotherapy for brain cancer.Expert Rev Neurother. 2011 Apr;11(4):533-43. doi: 10.1586/ern.11.40. Expert Rev Neurother. 2011. PMID: 21469926 Review.
Cited by
-
Identification of 3 subpopulations of tumor-infiltrating immune cells for malignant transformation of low-grade glioma.Cancer Cell Int. 2019 Oct 11;19:265. doi: 10.1186/s12935-019-0972-1. eCollection 2019. Cancer Cell Int. 2019. PMID: 31632199 Free PMC article.
-
EZH2 is a potential prognostic predictor of glioma.J Cell Mol Med. 2021 Jan;25(2):925-936. doi: 10.1111/jcmm.16149. Epub 2020 Dec 4. J Cell Mol Med. 2021. PMID: 33277782 Free PMC article.
-
Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.Expert Rev Neurother. 2019 Jul;19(7):663-677. doi: 10.1080/14737175.2019.1621169. Epub 2019 May 27. Expert Rev Neurother. 2019. PMID: 31106606 Free PMC article. Review.
-
Against the Resilience of High-Grade Gliomas: Gene Therapies (Part II).Brain Sci. 2021 Jul 23;11(8):976. doi: 10.3390/brainsci11080976. Brain Sci. 2021. PMID: 34439595 Free PMC article. Review.
-
Comprehensive Analysis of Sterol O-Acyltransferase 1 as a Prognostic Biomarker and Its Association With Immune Infiltration in Glioma.Front Oncol. 2022 May 12;12:896433. doi: 10.3389/fonc.2022.896433. eCollection 2022. Front Oncol. 2022. PMID: 35646697 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
